A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
Public ClinicalTrials.gov record NCT00111007. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase III Randomized, Placebo Controlled Study of Sorafenib in Repeated Cycles of 21 Days in Combination With Paclitaxel/Carboplatin Chemotherapy in Subjects With Unresectable Stage III or Stage IV Melanoma.
Study identification
- NCT ID
- NCT00111007
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 270 participants
Conditions and interventions
Conditions
Interventions
- Sorafenib (Nexavar, BAY43-9006) Drug
- Carboplatin/Paclitaxel Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2005
- Primary completion
- Aug 31, 2006
- Completion
- Dec 31, 2008
- Last update posted
- Oct 30, 2014
2005 – 2009
United States locations
- U.S. sites
- 19
- U.S. states
- 17
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35243 | — |
| Not listed | Tucson | Arizona | 85724 | — |
| Not listed | Los Angeles | California | 90025 | — |
| Not listed | Aurora | Colorado | 80045 | — |
| Not listed | Tampa | Florida | 33612 | — |
| Not listed | Chicago | Illinois | 60612 | — |
| Not listed | Park Ridge | Illinois | 60068 | — |
| Not listed | Louisville | Kentucky | 40202 | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | Omaha | Nebraska | 68114 | — |
| Not listed | Montclair | New Jersey | 07042 | — |
| Not listed | Buffalo | New York | 14263 | — |
| Not listed | New York | New York | 10065 | — |
| Not listed | Columbus | Ohio | 43221 | — |
| Not listed | Pittsburgh | Pennsylvania | 15232 | — |
| Not listed | Nashville | Tennessee | 37232-6307 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | Charlottesville | Virginia | 22908 | — |
| Not listed | Seattle | Washington | 98109-1023 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00111007, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 30, 2014 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00111007 live on ClinicalTrials.gov.